Table 3.
Characteristics of 7,335 patients aged 50–80 years in the hospital and community cohort with younger age group, diagnosed 1997–2015
| Hospital Cohort (n=6499) |
Community Cohort (n=836) |
|||||||
|---|---|---|---|---|---|---|---|---|
| Characteristics | Younger age group* | USPSTF criteria† | Total | P value | Younger age group* | USPSTF criteria† | Total | P value |
| (N=630) | (N=5869) | (N=6499) | (N=78) | (N=758) | (N=836) | |||
| Age at diagnosis, mean (SD), year | 52·1 (1·4) | 66·7 (6 ·5) | 65 ·3 (7·6) | <0 ·0001 | 52·3 (1·4) | 67·8 (6·7) | 66·3 (7·8) | <0 ·0001 |
| Sex, No. (%) | ||||||||
| Female | 285 (45·2%) | 2477 (42·2%) | 2762 (42·5%) | <0 0001 | 39 (50· 0%) | 317 (41·8%) | 356 (42 ·6%) | 0·16 |
| Male | 345 (54 ·8%) | 3392 (57·8%) | 3737 (57·5%) | 39 (50· 0%) | 441 (58 ·2%) | 480 (57 ·4%) | ||
| Race/ethnicity, No. (%) | ||||||||
| Caucasian | 534 (84·8%) | 5210 (88 ·8%) | 5744 (88 ·4%) | 0 ·003 | 76 (97· 4%) | 731 (96 ·4%) | 807 (96 ·5%) | 0·65 |
| Others | 96 (15 ·2%) | 659 (11· 2%) | 755 (11 ·6%) | 2 (2·6%) | 27 (3·6%) | 29 (3·5%) | ||
| Cigarette smoking status at diagnosis, No. (%) | ||||||||
| Former | 114 (18·1%) | 2262 (38·5%) | 2376 (36 ·6%) | <0 ·0001 | 17 (21·8%) | 296 (39 ·1%) | 313 (37·4%) | 0· 003 |
| Current | 516 (819%) | 3607 (61 5%) | 4123 (63 4%) | 61 (78· 2%) | 46·2 (60 ·9%) | 523 (62·6%) | ||
| Pack-years, median (IQR)‡ | 48 (35 0,65 0) | 56 (44 0,80 0) | 55 (43 0,80 0) | <0 0001 | 45 (36 ·0,64 ·0) | 60 (46· 0,80 ·0) | 60 (45 ·0,80 ·0) | <0· 0001 |
| Tumor stage, No. (%)§ | ||||||||
| NSCLC, No. (%) | 527 (83·7%) | 4864 (82 ·9%) | 5391 (83· 0%) | 66 (84 ·6%) | 625 (82·5%) | 691 (82 ·7%) | ||
| I | 69 (13·1%) | 1300 (26· 7%) | 1369 (25· 4%) | 16 (24 ·2%) | 199 (31·8%) | 215 (31·1%) | ||
| II | 61 (11·6%) | 538 (11 ·1%) | 599 (11· 1%) | <0· 0001 | 4 (6 ·1%) | 48 (7·7%) | 52 (7·5%) | 0·50 |
| III | 172 (32·6%) | 1388 (28 ·5%) | 1560 (28 9%) | 19 (28 ·8%) | 170 (27·2%) | 189 (27· 4%) | ||
| IV | 225 (42··7%) | 1638 (33· ·7%) | 1863 (34 ·6%) | 27 (40 ·9%) | 208 (33·3%) | 235 (34·0%) | ||
| SCLC, No. (%) | 89 (14·1%) | 901 (154%) | 990 (15 ·2%) | 12 (15·4%) | 133 (17·5%) | 145 (17·3%) | ||
| Limited | 38 (42··7%) | 399 (44 ·3%) | 437 (44 ·1%) | 0·77 | 3 (25·0%) | 51 (38·3%) | 54 (37·2%) | 0·36 |
| Extensive | 51 (57·3%) | 502 (55·7%) | 553 (55·9%) | 9 (75 ·0%) | 82 (61·7%) | 91 (62·8%) | ||
| Histology, No. (%) | ||||||||
| Adenocarcinoma | 298 (47·3%) | 2367 (40·3%) | 2665 (41· 0%) | 41 (52·6%) | 266 (35 ·1%) | 307 (36 ·7%) | ||
| Squamous cell carcinoma | 104 (16·5%) | 1612 (27·5%) | 1716 (26 ·4%) | 15 (19·2%) | 239 (31·5%) | 254 (30· 4%) | ||
| Small cell carcinoma | 91 (14·4%) | 915 (15·6%) | 1006 (15 ·5%) | <0 ·0001 | 12 (15·4%) | 135 (17·8%) | 147 (17·6%) | 0·02 |
| Other NSCLC|| | 23 (3–7%) | 178 (3 0%) | 201 (3 1%) | 2 (2–6%) | 48 (63%) | 50 (6 ·0%) | ||
| Unspecified NSCLC | 114 (18·1%) | 797 (13· 6%) | 911 (14·0%) | 8 (10·3%) | 70 (9 ·2%) | 78 (9·3%) | ||
| Treatment, No. (%)¶ | ||||||||
| Surgery only | 91 (14·4%) | 1359 (23·2%) | 1450 (22 ·3%) | 19 (24 ·4%) | 193 (25·5%) | 212 (25·4%) | ||
| Chemotherapy only | 131 (20 ·8%) | 975 (16 ·6%) | 1106 (17 ·0%) | <0 0001 | 12 (15·4%) | 116 (15·3%) | 128 (15·3%) | 0·75 |
| Chemotherapy & Radiation | 163 (25 ·9%) | 1150 (19·6%) | 1313 (20 ·2%) | 24 (30·8%) | 170 (22 ·4%) | 194 (23 ·2%) | ||
| Radiation only | 32 (5·1%) | 385 (6 ·6%) | 417 (6· 4%) | 5 (6· 4%) | 80 (10·6%) | 85 (10·2%) | ||
| Surgery & Chemotherapy | 35 (5·6%) | 300 (5 ·1%) | 335 (5·2%) | 4 (5 ·1%) | 28 (3·7%) | 32 (3·8%) | ||
| Surgery & Radiation | 12 (1·9%) | 128 (2·2%) | 140 (2· 2%) | 1 (1·3%) | 21 (2· 8%) | 22 (2·6%) | ||
| Surgery & Chemotherapy & Radiation | 57 (9· 0%) | 355 (6·0%) | 412 (6·3%) | 3 (3·8%) | 31 (4·1%) | 34 (4 ·1%) | ||
| Other treatment | 33 (5·2%) | 230 (3·9%) | 263 (4 ·0%) | 3 (3·9%) | 22 (2·9%) | 25 (3·0%) | ||
| No treatment | 57 (9· 0%) | 741 (12·6%) | 798 (12 ·3%) | 7 (9· 0%) | 97 (12·8%) | 104 (12·4%) | ||
Abbreviations: USPSTF, the U.S. Preventive Services Task Force; SD, standard deviation; IQR, interquartile range; NA, not applicable; NSCLC, non-small cell lung cancer; SCLC, small cell lung cancer.
Younger age group: individuals aged 50–54·9, who have a 30 or more pack-year smoking history, and currently smoke or have quitted within the past 15 years.
USPSTF criteria: individuals aged 55–80, who has a 30 or more pack-year smoking history, and currently smoke or have quitted within the past 15 years.
Pack-years: packs smoked daily × years for former smoker.
Unknown stage: 14 (2·2%) of 630 patients among the younger age group and 104 (1·8%) of 5869 patients among the USPSTF group in the hospital cohort
Large neuroendocrine and adenosquamous carcinoma
Unknown treatment: 19 (3%) of 630 patients among the younger age group and 246 (4·2%) of 5869 patients among the USPSTF group in the hospital cohort